(Q27659903)

3

object named as

Tse-I Lin

0 references

author name string

Maxwell D Cummings

1

0 references

Jimmy Lindberg

2

0 references

Herman de Kock

4

0 references

Oliver Lenz

5

0 references

Elisabet Lilja

6

0 references

Sara Felländer

7

0 references

Vera Baraznenok

8

0 references

Susanne Nyström

9

0 references

Magnus Nilsson

10

0 references

Lotta Vrang

11

0 references

Michael Edlund

12

0 references

Asa Rosenquist

13

0 references

Bertil Samuelsson

14

0 references

Kenneth Simmen

Angewandte Chemie International Edition

16

0 references

language of work or name

English

0 references

publication date

22 February 2010

0 references

published in

0 references

volume

49

0 references

issue

9

0 references

page(s)

1652-5

0 references

cites work

Molecular views of viral polyprotein processing revealed by the crystal structure of the hepatitis C virus bifunctional protease-helicase

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Discovery of small-molecule inhibitors of HCV NS3-4A protease as potential therapeutic agents against HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Macrocyclic inhibitors of HCV NS3 protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

The exploration of macrocycles for drug discovery--an underexploited structural class

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

The design of a potent inhibitor of the hepatitis C virus NS3 protease: BILN 2061--from the NMR tube to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

On the size of the active site in proteases. I. Papain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Novel potent macrocyclic inhibitors of the hepatitis C virus NS3 protease: use of cyclopentane and cyclopentene P2-motifs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Discovery of novel potent and selective dipeptide hepatitis C virus NS3/4A serine protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

The crystal structure of hepatitis C virus NS3 proteinase reveals a trypsin-like fold and a structural zinc binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Conformational changes in human hepatitis C virus NS3 protease upon binding of product-based inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Use of the fused NS4A peptide-NS3 protease domain to study the importance of the helicase domain for protease inhibitor binding to hepatitis C virus NS3-NS4A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Molecular modeling based approach to potent P2-P4 macrocyclic inhibitors of hepatitis C NS3/4A protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Impact of naturally occurring variants of HCV protease on the binding of different classes of protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Characterization of resistance mutations against HCV ketoamide protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FANIE.200906696